Apolipoprotein A1 (ApoA1), the major constituent of the high-density lipoprotein (HDL) molecule, exhibits anti-inflammatory properties. Our laboratory has previously shown that ApoA1 protects against switching of regulatory T (Treg) cells to atherogenic T follicular helper cells in Western diet-fed mice. However, the role of ApoA1 in modulating Treg cell homeostasis in the absence of atherosclerosis remains uncharacterized. Here, we show that ApoA1 is required for normal Treg cell homeostasis and functioning at steady state. Specifically, lack of ApoA1 decreased the numbers of both natural and induced Treg cells and also lowered Treg cell-based homeostatic proliferation and suppressive functions. Importantly, these changes occurred without affecting other T cell populations. Finally, we determined that the observed phenotypes were caused by changes to cholesterol content and reduced interleukin-2 (IL-2) receptor signaling in ApoA1deficient Treg cells. Overall, our results show that ApoA1-HDL is necessary for Treg cell homeostasis and functioning. Gaddis et al. -3
INTRODUCTION
Elevated, sustained levels of high-density lipoprotein (HDL) are associated with an increased risk for atherosclerosis and cardiovascular disease. Apolipoprotein AI (ApoA1) is the major protein component of HDL, accounting for approximately 70% of the molecule. ApoA1 is produced in the liver and is essential for the normal function of HDL (1) . Through ATP-binding cassette transporter A1 (ABCA1), ApoA1 promotes cholesterol efflux to form HDL (2) (3) (4) . ApoA1 thus aids in the excretion of cholesterol, a process that is beneficial for overall cardiovascular health.
Both HDL and ApoA1 have been shown to have anti-inflammatory properties (5) . For example, ectopic expression of ApoA1 in macrophages reduces immune infiltration in the aorta and protects against atherosclerosis in a cardiovascular disease mouse model (6) . Additionally, administration of ApoA1 reduces skin inflammation, T cell proliferation, and the ratio of effector T cells to regulatory T cells in mice with loss of both ApoA1 and the low-density lipoprotein receptor (LDLR) (7, 8) . More recently, our laboratory has found that ApoA1 prevents the switch of protective, regulatory T cells to atherogenic, inflammatory T follicular helper cells, and also reduces B cell germinal center formation and activation, in an atherogenic mouse model (9) . Importantly, these findings extend the anti-inflammatory effects of ApoA1 beyond cardiovascular disease. Indeed, ApoA1 attenuates neuroinflammation in a mouse model of Alzheimer's disease (10) and reduces lymphocyte activation and autoimmunity in a lupus mouse model (11) . Similarly, a model of rheumatoid arthritis shows reduction of autoimmune responses with the presence of ApoA1 (12) .
ApoA1 decreases the differentiation and maturation of human dendritic cells and thus dampens T cell activation (13) , suggesting that ApoA1 can influence T cell responses at steady state. However, the function of ApoA1 in the immune system during steady state has yet to be fully determined. Thus, we sought to determine the involvement of ApoA1 on T cell immune 
MATERIALS AND METHODS

Mice
Breeding pairs of C57BL/6 (B6), Apoa1 -/-, and CD45.1 mice were purchased from The Jackson Laboratory (Bar Harbor, Maine; Stock numbers 000664, 002055, and 002014, respectively). For mice with ABCA1 loss specifically in T cells, bone marrow chimeras were generated from bone marrow cells collected from Abca1 flox/flox and Abca1 flox/flox ;Lck-Cre +/mice (both from John S.
Parks, Wake Forest University). Recipient B6 mice were irradiated with 550 rads twice, four hours apart. Approximately 1x10 7 bone marrow cells were retro-orbitally injected into recipient mice. Recipient mice were then allowed to reconstitute for 10 weeks before they were sacrificed and their peri-aortic lymph nodes (PaLNs) were analyzed for Treg cells. were stimulated with recombinant human IL-2 (100 U/ml) (Peprotech, Rocky Hill, NJ) for 45 min at 37°C. Cells were then surface stained as previously described. Cells were washed and fixed with 1X Lyse/Fix buffer (BD Biosciences) for 10 min at 37°C. Cells were then washed and chilled on ice and permeabilized with pre-chilled BD phosphoflow Perm Buffer III for 30 min (BD Biosciences), followed by staining for Foxp3 and rabbit pSTAT5 (Cell Signaling Technologies, Beverly, MA), and then by secondary anti-rabbit-AF647 (eBioscience). Samples were acquired using an LSRII flow cytometer (BD, Bioscience, San Diego, CA) and data were analyzed using Flowjo Ver 9.8 and 10.0.08 (Tree Star, Ashland, OR).
In vivo proliferation assay
B6 and Apoa1 -/mice were given intraperitoneal injections of 1 mg of BrdU. PaLNs were then harvested 36 hours after injection. PaLN cell suspensions were stained as explained above.
Cells were then DNase treated and stained for BrdU as recommended by the BrdU Flow Kit (BD Biosciences).
Suppression assay
Treg cells (CD4 + CD25 + ) were sorted from spleens and peripheral LNs of B6 and Apoa1 -/mice. (Miltenyi Biotec, Auburn, CA), and then irradiated with 3000 rads. Feeders were cultured with naïve effector T cells at a ratio of 3:1 in U-shaped 96 well plates. Sorted Treg cells from B6 or Apoa1 -/mice were added at a ratio of 1:2, 1:4, or 1:8. Cells were then stimulated with soluble α CD3 antibody at 2.5 μ g/ml. All cells were cultured in RPMI media supplemented with 10 % FCS, L-glutamine, penicillin, streptomycin, and β -mercaptoethanol. Cells were harvested 4 days following stimulation and the percentage of effector CD45.1 cells that diluted CTV was determined.
In vitro Treg induction
Naïve CD4 T cells were sorted as described above or using EasySep™ Naïve CD4 T cell 
ELISA
Supernatants from in vitro Treg induction were collected following 2 days of stimulation and frozen at -80°C until analyzed. IL-2 ELISAs were performed using Ready-Set-Go ELISA kits (eBioscience) according to manufacturer's instruction.
Statistical analyses
All results are expressed as means (± SEM). Results were analyzed by unpaired, two-tailed Student's t-tests. p values of < 0.05 were considered to be statistically significant. Statistical analyses were performed using GraphPad Prism software version 6 (GraphPad Software, Inc.).
RESULTS
ApoA1 is required for optimal Treg cell homeostasis in steady state
To determine the role of ApoA1 in Treg cell development during steady state, we compared Treg cells in the peri-aortic lymph nodes (PaLNs) of Apoa1 -/mice to wild-type, C57BL/6 (B6) mice. We found a decrease in the percentages and numbers of CD4 + CD25 + Foxp3 + Tregs (~ 27 % and 50 %, respectively) in Apoa1 -/mice compared to B6 controls (Figure 1A) . These changes were accompanied by an approximately 50 % decrease in the expression of latent, membrane-bound transforming growth factor β (TGFβ) on Treg cells (Figure 1B) . There was also an almost 50 % decrease in the numbers of naturally occurring Treg cells in Apoa1 -/mice, as indicated by a decrease in the number of Treg cells positive for neuropilin1 (NRP1), a marker for thymus-derived Treg cells (14, 15) (Figure 1C) . Furthermore, we found no changes in effector or memory CD4 T cell development (Figure 1D) or the ability of CD4 T cells to produce interferon (IFN)-γ or interleukin (IL)-17 (Figure 1E) in Apoa1 -/mice. Finally, the observed reduction in peripheral Treg cells was not due to a decrease in the percentages or numbers of Treg cells in the thymus (Figure 1F) , suggesting a defect specifically in Treg cell homeostasis.
ApoA1-deficient Treg cells show reduced proliferative and suppressive capacities
We next sought to examine if the decreased numbers of Treg cells in Apoa1 -/mice were due to a defect in their homeostatic, proliferative capacity. Thus, BrdU injection in B6 and Apoa1 -/mice revealed an approximately 30% decrease in the proliferative capacity of Apoa1 -/-Treg cells in PaLNs, compared to B6 cells (Figure 2A) . Moreover, this defect was only detected in Treg cells and not in naïve or memory CD4 T cells (Figure 2A) 
. Treg cells in PaLNs of
Apoa1 -/mice also showed no differences in their rates of apoptosis, as measured by the frequency and number of caspase3 + Treg cells (Figure 2B) . These data suggest that the reduction of the number of Treg cells in Apoa1 -/mice is not due to an increase in Treg cell apoptosis but rather a defect in their proliferative capacity.
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To determine whether ApoA1 had any direct effect on Treg cell function, we tested the ability of Treg cells from Apoa1 -/mice to suppress the proliferation of effector CD4 T cells. We observed that ApoA1 -/-Treg cells had a lower suppressive capacity than B6 Treg cells, (~ 55% versus ~ 38% of effector cells dividing in a 2:1 Teff:Treg culture, respectively) ( Figure 2C) .
These results suggest that ApoA1 is critical for homeostatic proliferation and functioning of peripheral Treg cells during steady state.
Loss of ApoA1 increases Treg cell cholesterol content
Since ApoA1 facilitates cholesterol efflux, we hypothesized that Treg cells from Apoa1 -/mice would display altered cholesterol processing. Thus, we measured levels of intracellular cholesterol by filipin III staining and observed a significant increase in the fluorescence intensity of filipin III in Apoa1 -/-Treg cells compared to those from B6 mice (Figure 3A) . ApoA1 couples the cholesterol transporter ATP-binding cassette transporter A1 (ABCA1) to allow efflux of cellular cholesterol. We therefore tested if mice with T cell-specific deletion of ABCA1 displayed defects in Treg development. We found a ~ 20 % decrease in the percentages of Treg cells in mice lacking ABCA1 in T cells (Figure 3B) . Together, these data suggest that defects in cholesterol transport by either loss of ApoA1 or ABCA1 impairs Treg cell homeostasis.
Apoa1 -/-Treg cells have a defect in IL-2 signaling
Signaling by IL-2 is essential for the stability and homeostatic proliferation of Treg cells. Therefore, we next checked for defective IL-2 signaling in Treg cells from Apoa1 -/mice by examining the levels of phosphorylation of signal transducer and activator of transcription 5 (STAT5), the signaling molecule downstream of the IL-2 receptor. Upon stimulation with IL-2, Treg cells from Apoa1 -/showed reduced phosphorylation of STAT5 compared to Treg cells from B6 mice (Figure 4A) . This defect in IL-2 signaling was not observed in naïve or memory CD4 T cells (Figure 4B ), suggesting that changes in IL-2 signaling are specifically responsible for the changes observed in Treg cells from Apoa1 -/mice.
IL-2 can rescue Apoa1 -/-Treg cell induction
Gaddis et al. -10 We next sought to answer whether induction of naïve T cells to Treg cells was impacted by loss of ApoA1. To accomplish this, naïve CD4 T cells from B6 and Apoa1 -/mice were treated with α CD3, α CD28, and TGFβ to derive induced Treg (iTreg) cells in vitro. After treatment, fewer iTreg cells were generated from Apoa1 -/naïve T cells compared to B6 cells (27.5 ± 4.1 % versus 42.9 ± 2.4 %, respectively) (Figure 5A) , suggesting that ApoA1 also impacts iTreg generation. When supernatants from these cultures were examined, we found a decrease in the amount of IL-2 produced by cultured Treg cells from Apoa1 -/mice compared to those from control mice (Figure 5B) . This decrease was accompanied by a reduction in both Foxp3 and CD25 (IL-2Rα) expression ( Figure 5C) . Upon adding exogenous IL-2 to culture conditions, we observed a rescue of the percentages of iTreg cells from Apoa1 -/naïve T cells to levels comparable with B6 cells (Figure 5C ). This was also accompanied by increases in both Foxp3 and CD25 levels, supporting the notion that the reduction in Treg cell numbers in Apoa1 -/cells is dependent on IL-2 signaling deficits.
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DISCUSSION
The objective of this study was to determine the role of ApoA1 in Treg cell development during steady state. We found that loss of ApoA1 affects Treg cell homeostasis and function. We observed this defect in both naturally occurring Treg cells as well as induced Treg cells from ApoA1-deficient mice. Importantly, we also found that loss of ApoA1 does not affect either naïve effector or memory CD4 T cells. A number of laboratories including our own have shown that administration of ApoA1 protects against Treg cell loss and conversion of Treg cells to inflammatory T cells during atherosclerosis progression (7) (8) (9) . In addition, ApoA1 has been shown to reduce inflammation as well as lymphocyte involvement in inflammatory conditions such as rheumatoid arthritis and lupus (11, 12) . In this report, our results show that ApoA1 is inherently beneficial to Treg cell homeostasis, regardless of the atherosclerotic or inflammation status of the host.
We found an accumulation of cholesterol in Treg cells from ApoA1-deficient mice, suggesting that lack of ApoA1 causes disruptions in normal Treg cell cholesterol homeostasis. This is observation is consistent with the previous finding that chimeras with loss of ABCA1 exhibit a similar defect in Treg cell homeostasis. Furthermore, these results are in agreement with work from our laboratory which demonstrates that loss of the cholesterol transporter ATPbinding cassette subfamily G member 1 (ABCG1) impacts both T cell and thymic and peripheral Treg cell development (16) (17) .
The results presented here show that lack of ApoA1 causes perturbations in IL-2 receptor signaling and STAT-5 phosphorylation. Lipid rafts in the plasma membrane play an important role in T cell functioning (18) . Since IL-2 receptor signaling occurs at the plasma membrane on lipid rafts, changes in plasma membrane cholesterol composition could affect the signaling ability of the IL-2 receptor. In fact, minor changes in cholesterol content and plasma membrane lipids can alter IL-2 signaling events (19, 20) and subsequently affect phosphorylation of STAT5. IL-2 is essential for Treg cell expression of Foxp3, a transcription Gaddis et al. -12 factor critically involved in Treg cell development (21) . Concordant with this, here we showed that addition of exogenous IL-2 increased levels of Foxp3 protein expression and rescued defects in Treg cell induction from Apoa1 -/-, naïve T cells in vitro. We have previously reported that administration of ApoA1 in atherosclerotic mice can increase IL-2Rα levels on Treg cells (9) . Thus, our results indicate that ApoA1 regulation of IL-2/IL-2R signaling can occur at steady state and in the absence of atherosclerosis.
The benefits of ApoA1 as a protective, anti-inflammatory agent and as an immune system regulator have been well documented (10, 11, 13, 22, 23) . Lack of ApoA1 increases T cell proliferation and release of inflammatory cytokines IFN-γ and IL-17 in a rheumatoid arthritis animal model (12) . Similarly, Apoa1 transgenic mice, which display increased levels of ApoA1, are protected against lupus and show reduced lymphocyte activation (11) . A more recent study examining the role of ApoA1 binding protein (AIBP) showed that inhalation of AIBP lowered lipopolysaccharide (LPS)-induced airway neutrophilia and lung injury in mice (24) . These effects are seen outside of the protective role of ApoA1 in the cardiovascular system, suggesting that the benefits of ApoA1 extend beyond heart disease. Indeed, our results demonstrate that ApoA1 can act as an immune modulator in inflammatory disease, helping increase the protective Treg cell population and putting a check on activated effector T cells. Whether infusion of lipid-free ApoA1 can affect the percentages of Treg cells in atherosclerosis is yet to be determined. Finally, whether or not increased levels of ApoA1 are protective against other inflammatory conditions is unknown. Future work focused on answering these questions may lead to improved therapeutics for inflammatory conditions such as atherosclerosis.
